• Summit Therapeutics is like a very early-stage Amgen or Gilead Sciences, focused purely on developing novel cancer drugs with no approved products yet.
• Imagine a Genentech or Vertex Pharmaceuticals in their early years, as a biotech company dedicated to researching and testing new, potentially breakthrough cancer treatments.
• Consider it as a portfolio of promising experimental cancer drugs undergoing clinical trials, similar to Moderna or BioNTech before their vaccines were approved and successful.

Summit Therapeutics (SMMT) is a clinical-stage biotechnology company focused on developing therapies for serious diseases. Its major product candidates include:

• Ivonescimab (AK112/SMT112): A novel bispecific antibody combining PD-1 and VEGF blockade, being developed for patients with non-small cell lung cancer (NSCLC) and other solid tumors.
• Acinicimab (SMT022): A humanized antibody targeting the CD47-SIRPα pathway, currently in development for various cancers.

Summit Therapeutics (SMMT) is a biotechnology company focused on developing and commercializing oncology treatments. As such, it sells its pharmaceutical products primarily to **other companies and institutions** within the healthcare supply chain, rather than directly to individual patients.

The major customers for pharmaceutical manufacturers like Summit Therapeutics are typically large wholesale drug distributors, who then supply hospitals, pharmacies, and other healthcare providers.

Based on the standard pharmaceutical distribution model in the United States, the primary customer companies that Summit Therapeutics will sell its products to are likely the major pharmaceutical wholesalers. While specific contracts or revenue percentages with each may not be individually disclosed by Summit at this stage of commercialization, the industry's major distributors typically include:

• McKesson Corporation (NYSE: MCK)
• Cardinal Health, Inc. (NYSE: CAH)
• AmerisourceBergen Corporation (NYSE: ABC)

These distributors act as intermediaries, purchasing drugs directly from manufacturers and then distributing them to the vast network of hospitals, clinics, specialty pharmacies, and retail pharmacies across the country, which ultimately administer or dispense the drugs to patients.

Major Suppliers for Summit Therapeutics (SMMT):

• Akeso Inc. (HKEX: 9926)

Robert W. Duggan, Co-CEO & Executive Chairman

Robert W. Duggan joined Summit Therapeutics' Board of Directors in December 2019, became Chief Executive Officer in April 2020, and has served as Executive Chairman of the Board since February 2020. Since 2015, he has been the Founder and CEO of Duggan Investments, a venture capital and equity investment firm. From 2008 to 2015, Mr. Duggan was Chairman, CEO, and the largest investor in Pharmacyclics, Inc., a developer of small-molecule medicines for cancer treatment. He led the collaboration and license deal for ibrutinib with Johnson & Johnson in 2011 and the subsequent sale of Pharmacyclics to AbbVie Inc. in 2015 for approximately $21 billion, one of the largest transactions in the pharmaceutical and biotechnology industries. Prior to that, from 1990 to 2003, Mr. Duggan was Chairman of the Board of Computer Motion, Inc., a robotic surgery company, and also served as CEO from 1997 to 2003. Computer Motion merged with Intuitive Surgical, Inc. in 2003, and Mr. Duggan served on Intuitive Surgical's Board of Directors until 2011. He is also the majority shareholder and CEO of Pulse Biosciences.

Manmeet Soni, Chief Operating Officer, Chief Financial Officer & Director

Manmeet Soni was appointed Chief Financial Officer on April 2, 2024, in addition to his role as Chief Operating Officer, which he assumed upon joining Summit Therapeutics in October 2023. Prior to joining Summit, Mr. Soni served as President, Chief Operating Officer, and Chief Financial Officer of Reata Pharmaceuticals, Inc., where his tenure concluded with its sale to Biogen Inc. for $7.5 billion. He was also the Senior Vice President and Chief Financial Officer of Alnylam Pharmaceuticals, Inc. from May 2017 to August 2019. Additionally, Mr. Soni served as Executive Vice President, Chief Financial Officer, and Treasurer of ARIAD Pharmaceuticals, Inc. during its acquisition by Takeda Pharmaceutical Company Limited. He previously held the position of Chief Financial Officer and Treasurer of Pharmacyclics, Inc. until its acquisition by AbbVie in 2015. Before Pharmacyclics, he was the corporate controller at ZELTIQ Aesthetics Inc. and a Senior Manager-Life Science at PricewaterhouseCoopers LLP.

Mahkam Zanganeh, Co-CEO, President & Director

Dr. Mahkam Zanganeh is Co-CEO, President, and a Director of Summit Therapeutics. She previously served as Chief Operating Officer of Pharmacyclics, where she was instrumental in the global success of ibrutinib, a breakthrough blood cancer therapy. Her leadership played a central role in the $21 billion acquisition of Pharmacyclics by AbbVie, one of the largest biotechnology transactions in history.

Dave Gancarz, Chief Business Officer; Chief Strategy Officer

Dave Gancarz serves as Chief Business Officer and Chief Strategy Officer for Summit Therapeutics, having joined the company in November 2020. He is also listed as the Investor Relations Contact.

Allen S. Yang, Chief Medical Officer

Allen S. Yang is the Chief Medical Officer at Summit Therapeutics.

The key risks to Summit Therapeutics (SMMT) are primarily centered on the success of its lead drug candidate, its financial stability, and ongoing legal and regulatory challenges.

1. Heavy Reliance on Ivonescimab and Clinical/Regulatory Hurdles: Summit Therapeutics' business is highly dependent on the successful global clinical development, regulatory approval, and commercialization of its lead product candidate, ivonescimab. The drug's success hinges on factors such as successful clinical trials, obtaining regulatory approvals in key markets like the U.S. and EU, and establishing manufacturing and sales capabilities. While recent Phase III HARMONi trial results showed promising progression-free survival (PFS), the lack of statistically significant overall survival (OS) data presents a critical challenge for securing U.S. regulatory approval. Any delays or failures in these areas could lead to significant financial losses and severely impact the company's future prospects.
2. Significant Financial Risks and Need for Additional Capital: As a development-stage company, Summit Therapeutics consistently experiences substantial operating losses and has an accumulated deficit. The company anticipates continued losses and requires significant additional capital to fund its ongoing operations and meet substantial obligations under its license agreement, which includes potential contingent payments to Akeso totaling up to $4.56 billion. Summit plans to raise these necessary funds through various means, including equity or debt offerings, collaborations, and strategic alliances. However, there is inherent uncertainty regarding the company's ability to achieve profitability and maintain sufficient liquidity, given its high cash burn rate.
3. Legal and Regulatory Challenges: Summit Therapeutics operates in a highly regulated industry and must navigate complex and evolving regulatory requirements across multiple jurisdictions. Changes in these regulations or delays in obtaining product approvals could hinder the company's ability to bring its therapies to market. Furthermore, the company is currently subject to ongoing legal investigations into potential securities fraud and alleged misrepresentations concerning its financial health and operational integrity. These legal proceedings could result in significant financial liabilities and have a detrimental impact on investor confidence and the company's reputation.

Summit Therapeutics' primary product is **ivonescimab**, a novel bispecific antibody designed to target both PD-1 and VEGF pathways in oncology. The company is primarily focused on developing ivonescimab for various indications within non-small cell lung cancer (NSCLC).

The addressable markets for ivonescimab in non-small cell lung cancer include:

• The total addressable market for checkpoint inhibitors, which includes NSCLC, is estimated to be over **$90 billion globally by 2028**.
• Specifically, the NSCLC portion of the checkpoint inhibitor market represents more than **$20 billion of that opportunity globally by 2028**.
• For first-line wild-type NSCLC, there is an annual market opportunity of more than **$10 billion globally**.
• For post-TKI EGFR-mutant NSCLC, the annual sales potential is estimated to be around **$500 million to $1 billion globally**.
• Analysts estimate that a U.S. approval for ivonescimab in first-line squamous NSCLC could unlock **$2 billion in annual sales by 2030**, assuming 15% market penetration.
• Overall, analysts project that ivonescimab could generate over **$1 billion in annual sales by the end of the decade**.

Summit Therapeutics holds licensing rights for ivonescimab in the United States, Canada, Europe, Japan, Latin America, the Middle East, and Africa.

Summit Therapeutics (SMMT) is poised for significant future revenue growth over the next 2-3 years, primarily driven by its lead drug candidate, ivonescimab. Key growth drivers include regulatory approvals, expansion into new indications, and the drug's differentiated clinical profile.

1. Regulatory Approval and Commercial Launch of Ivonescimab in Non-Small Cell Lung Cancer (NSCLC) in Key Markets: The most significant driver for Summit Therapeutics' future revenue growth is the anticipated regulatory approval and subsequent commercial launch of ivonescimab in major markets, particularly the United States and Europe. Summit plans to submit a Biologics License Application (BLA) in the fourth quarter of 2025 for ivonescimab in combination with chemotherapy for patients with EGFR-mutated, third-generation EGFR-TKI-resistant, non-squamous NSCLC, based on positive results from the HARMONi-A study. Additionally, ivonescimab has demonstrated impressive efficacy in the HARMONi-6 study for advanced squamous NSCLC. The company is also advancing the HARMONi and HARMONi-3 studies, with full enrollment for the squamous cohort of HARMONi-3 expected in the first half of 2026. Analysts project potential annual sales of $2 billion by 2030 if ivonescimab achieves a 15% market share in first-line squamous NSCLC in the U.S.

2. Expansion of Ivonescimab into Additional Solid Tumor Indications: Beyond NSCLC, Summit is actively pursuing the expansion of ivonescimab into other solid tumor types, significantly broadening its potential market. The company intends to initiate a global Phase III trial (HARMONi-GI3) in first-line unresectable colorectal cancer by the end of 2025 and is evaluating ivonescimab in various other solid tumors, including breast, head and neck, biliary tract, and pancreatic cancer, with a total of 14 planned or ongoing Phase III trials. Collaborations with institutions like MD Anderson Cancer Center and partnerships, such as those with Revolution Medicines for RAS-mutant cancers, further underscore the strategy to diversify ivonescimab's therapeutic applications.

3. Strong Clinical Differentiation and Efficacy of Ivonescimab: Ivonescimab's unique dual mechanism, targeting both PD-1 and VEGF pathways with a single bispecific antibody, provides a significant competitive advantage. This dual action has shown superior efficacy in Phase III lung cancer trials, demonstrating a 48-49% reduced risk of progression or death compared to existing PD-1 inhibitors like Keytruda in squamous NSCLC. Furthermore, ivonescimab is engineered with a shorter half-life, which is intended to reduce the toxicity risks historically associated with anti-VEGF therapies, thereby offering a more favorable safety profile. This differentiated profile positions ivonescimab as a potential new standard of care, driving adoption and market share upon approval.

4. Strategic Collaborations and Partnerships: Summit's ability to forge and expand strategic collaborations represents another potential revenue driver. High-profile discussions, such as a reported licensing deal with AstraZeneca worth up to $15 billion, highlight the significant market potential recognized by larger pharmaceutical players. Such collaborations could yield substantial upfront payments, milestone payments, and/or shared profits, providing significant non-dilutive funding and bolstering revenue streams as ivonescimab advances through development and commercialization.

Share Issuance

• In March 2023, Summit Therapeutics completed a fully-subscribed $500 million rights offering, selling approximately 476.2 million shares of common stock at $1.05 per share.
• In October 2025, the company announced a private placement of approximately 26.68 million shares of common stock at $18.74 per share, generating gross proceeds of around $500.0 million.
• In August 2025, Summit amended its Distribution Agreement to allow for an "at-the-market" (ATM) offering of up to $360.0 million in additional shares of common stock.

Inbound Investments

• In December 2022, Summit Therapeutics entered into a Collaboration and License Agreement with Akeso, Inc. to in-license intellectual property for ivonescimab, making an upfront payment in Q1 2023 consisting of $474.9 million cash and 10 million shares of common stock (valued at $25.1 million).
• In June 2024, Summit amended the License Agreement with Akeso, Inc. to expand ivonescimab's territories to include Latin America, the Middle East, and Africa, for an upfront cash payment of $15.0 million in Q3 2024.
• In October 2025, Akeso, Inc. invested $10 million in Summit's $500 million private placement.

Capital Expenditures

• Summit Therapeutics' capital expenditures were approximately $0.42 million in 2020, $0.31 million in 2021, $0.62 million in 2022, -$0.10 million in 2023, and $0.14 million in 2024.